Note 20 - Restructuring

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Restructuring and Related Activities Disclosure [Text Block]

20.

Restructuring

During the

third

quarter of

2017,

the Company’s management committed to a plan to terminate various government grants that were acquired as part of the acquisition of Immunetics. As a result, the Company terminated

15

employees during the

fourth

quarter of

2017

and recorded restructuring charges of

$169,000

in research and development expense and

$13,000

in general and administrative expense.

A summary of these charges and payments made to date are included in the below table. Accrued restructuring costs at

December 31, 2018

and

2017

are included in accrued liabilities in the accompanying balance sheet.

(in thousands)	Severance
Balance at December 31, 2016	$	—
Charge for restructuring		182
Payments during 2017		(108	)
Balance at December 31, 2017		74
Payments during 2018		(70	)
Balance at December 31, 2018	$	4

In addition to the items listed above, the Company recorded charges in the

third

quarter of

2017

of

$28,000

to write-off equipment having

no

future benefit to the Company and

$26,000

to write-off the unamortized balance of the grant intangible.